BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tolododekin Alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tolododekin Alfa\, from ClinicalTrials.go
 v estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06171750-2206@assetmemo.bio
DTSTAMP:20261121T005930Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Tolododekin Alfa: Phase 1 readout est. (NCT06171750)
DESCRIPTION:Tolododekin Alfa\, phase 1\, Non-Small Cell Lung Cancer.\nStudy
 : Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors\nEs
 timated primary completion: April 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tolododekin-alfa#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06171750
URL:https://assetmemo.bio/drug/tolododekin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027514-2206@assetmemo.bio
DTSTAMP:20261121T005930Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tolododekin Alfa: Phase 1 readout est. (NCT07027514)
DESCRIPTION:Tolododekin Alfa\, phase 1\, Non-Small Cell Lung Cancer.\nStudy
 : A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/P
 D-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tolododekin-alfa#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07027514
URL:https://assetmemo.bio/drug/tolododekin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
